Related Experiment Video
Updated: Aug 11, 2026

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Outcomes for children with cardiomyopathy awaiting transplantation
L E Nield1, B W McCrindle, D J Bohn
1Department of Paediatrics, The Hospital for Sick Children, The University of Toronto School of Medicine, Ontario, Canada.
Insights
Children with cardiomyopathy awaiting heart transplantation face a 16% mortality risk, particularly those in critical clinical states at listing. Early transplantation improves survival chances for pediatric heart failure patients.
Area of Science:
- Pediatric Cardiology
- Transplantation Medicine
- Cardiovascular Research
Background:
- Childhood cardiomyopathies are a diverse group of diseases with often poor prognoses.
- Cardiac transplantation is a critical intervention for children with end-stage heart failure due to cardiomyopathy.
Purpose of the Study:
- To identify factors influencing outcomes for children with cardiomyopathy listed for heart transplantation.
- To analyze mortality and survival rates in pediatric cardiomyopathy patients awaiting cardiac transplant.
Main Methods:
- Historical cohort study of children with cardiomyopathy listed for transplantation between December 1989 and April 1998.
- Analysis of patient demographics, cardiomyopathy type, clinical status at listing, and transplantation outcomes.
Main Results:
- Out of 31 children listed, 23 (74%) received transplants, with a median wait time of 54 days.
- Mortality before transplantation was 16% (5 patients), with higher risk in females and those in critical clinical states (NYHA class III/IV).
- Mechanical ventricular assistance did not predict adverse outcomes; factors like ACE inhibitor use and better cardiac function were associated with improved survival to transplant.
Conclusions:
- Pediatric cardiomyopathy patients awaiting heart transplantation have a significant 16% mortality rate.
- Clinical status at the time of listing is a key determinant of outcomes for these children.
Objective:
To determine factors associated with outcomes after listing for transplantation in children with cardiomyopathies.
Background:
Childhood cardiomyopathies form a heterogeneous group of diseases, and in many, the prognosis is poor, irrespective of the etiology. When profound heart failure develops, cardiac transplantation can be the only viable option for survival.
Methods:
We included all children with cardiomyopathy listed for transplantation between 12/89 and 4/98 in this historical cohort study.
Results:
We listed 31 patients, 15 male and 16 female, 27 with dilated and 4 with restrictive cardiomyopathy, for transplantation. The median age at listing was 5.7 years, with a range from fetal life to 17.8 years. Transplantation was achieved in 23 (74%), with a median interval from listing of 54 days, and a range from zero to 11.4 years. Of the patients, 14 were transplanted within 30 days of listing. Five patients (16%) died before transplantation. Within the Canadian algorithm, one of these was in the third state, and four in the fourth state. One patient was removed from the list after 12 days, having recovered from myocarditis, and two remain waiting transplantation after intervals of 121 and 476 days, respectively. Patients who died were more likely to be female (5/5 vs. 11/26; p=0.04) and to have been in the third or fourth states at listing (5/5 vs. 15/26; p=0.04). The use of mechanical ventricular assistance, in 10 patients, was not a predictor of an adverse outcome. While not statistically significant, survival to transplantation was associated with treatment using inhibitors of angiotensin converting enzyme, less mitral regurgitation, a higher mean ejection fraction and cardiac index, and lower right ventricular systolic pressure.
Conclusions:
Children with cardiomyopathy awaiting transplantation have a mortality of 16% related to their clinical state at the time of listing.
More Related Videos
Related Concept Videos
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Kidney Transplant I: Introduction

